Baricitinib (BioDeep_00000176437)
human metabolite blood metabolite
代谢物信息卡片
2-[1-(Ethanesulphonyl)-3-(4-{1h-pyrrolo[2,3-D]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile
化学式: C16H17N7O2S (371.1164382)
中文名称: 巴瑞克替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
InChI: InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials, DrugBank
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
7 个代谢物同义名
2-[1-(Ethanesulphonyl)-3-(4-{1h-pyrrolo[2,3-D]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile; 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile; 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}pyrazol-1-yl)azetidin-3-yl]acetonitrile; INCB-28050ly3009104; Baricitinib; INCB028050; Olumiant
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:95341
- PubChem: 44205240
- HMDB: HMDB0248873
- DrugBank: DB11817
- ChEMBL: CHEMBL2105759
- Wikipedia: Baricitinib
- chemspider: 26373084
- CAS: 1187594-09-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Shiheng Wang, Wanling Ning, Hanqing Tang, Chaochao Mu, Xiaosong Huang. Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus.
Arthritis research & therapy.
2024 May; 26(1):98. doi:
10.1186/s13075-024-03331-8. [PMID: 38730460] - Hongming Hu, Shasha Wang. Baricitinib rapidly improves mechanic's hands and hiker's feet in anti-synthetase syndrome.
Rheumatology (Oxford, England).
2024 Feb; 63(2):e65-e66. doi:
10.1093/rheumatology/kead357. [PMID: 37458479] - Qingying He, Xin Xie, Qian Chen, Wenquan Li, Zongzhou Song, Xurui Wang, Xiao Ma, Jinhao Zeng, Jing Guo. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
Frontiers in immunology.
2024; 15(?):1342810. doi:
10.3389/fimmu.2024.1342810. [PMID: 38464512] - Ziyi Sun, Rongqi Li, Yingai Wang, Feng Han, Wei Wei, Xin Li. Efficacy of Baricitinib in Patients with Refractory Adult-Onset Still's Disease.
Drugs in R&D.
2023 Jun; 23(2):109-120. doi:
10.1007/s40268-023-00417-7. [PMID: 37010773] - Ramona Hartinger, Eva-Maria Lederer, Elisa Schena, Giovanna Lattanzi, Karima Djabali. Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
Cells.
2023 05; 12(10):. doi:
10.3390/cells12101350. [PMID: 37408186] - Axel De Greef, Pierre-Dominique Ghislain, Laurence de Montjoye, Marie Baeck. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
Advances in therapy.
2023 05; 40(5):2509-2514. doi:
10.1007/s12325-023-02490-5. [PMID: 36944819] - Mohsin Kazi, Yousef Alanazi, Ashok Kumar, Ahmad Abdul-Wahhab Shahba, Syed Rizwan Ahamad, Khalid M Alghamdi. Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib: A Paradigmatic Case of Drug Repositioning for Cancer Management.
Molecules (Basel, Switzerland).
2023 Feb; 28(5):. doi:
10.3390/molecules28052237. [PMID: 36903483] - Zhongjian Wang, Wei Liu, Xueyan Li, Hongjiao Chen, Dongying Qi, Fulu Pan, Huining Liu, Shuang Yu, Bowen Yi, Guopeng Wang, Yang Liu. Physiologically based pharmacokinetic combined JAK2 occupancy modelling to simulate PK and PD of baricitinib with kidney transporter inhibitors and in patients with hepatic/renal impairment.
Regulatory toxicology and pharmacology : RTP.
2022 Aug; 133(?):105210. doi:
10.1016/j.yrtph.2022.105210. [PMID: 35700864] - Ziteng Wang, Eric Chun Yong Chan. Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics.
Clinical pharmacology and therapeutics.
2022 Aug; 112(2):291-296. doi:
10.1002/cpt.2600. [PMID: 35380176] - Rita Rubin. Baricitinib Is First Approved COVID-19 Immunomodulatory Treatment.
JAMA.
2022 06; 327(23):2281. doi:
10.1001/jama.2022.9846. [PMID: 35727290] - Brian Dobosh, Keivan Zandi, Diego Moncada Giraldo, Shu Ling Goh, Kathryn Musall, Milagros Aldeco, Julia LeCher, Vincent D Giacalone, Junkai Yang, Devon J Eddins, Manoj Bhasin, Eliver Ghosn, Vikas Sukhatme, Raymond F Schinazi, Rabindra Tirouvanziam. Baricitinib attenuates the proinflammatory phase of COVID-19 driven by lung-infiltrating monocytes.
Cell reports.
2022 Jun; 39(11):110945. doi:
10.1016/j.celrep.2022.110945. [PMID: 35688145] - NULL. COVID-19 update: Baricitinib (Olumiant) FDA-approved for treatment of COVID-19.
The Medical letter on drugs and therapeutics.
2022 06; 64(1652):e2-e3. doi:
NULL. [PMID: 35657369] - Sarah E Nystrom, Guojie Li, Somenath Datta, Karen L Soldano, Daniel Silas, Astrid Weins, Gentzon Hall, David B Thomas, Opeyemi A Olabisi. JAK inhibitor blocks COVID-19 cytokine-induced JAK/STAT/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids.
JCI insight.
2022 06; 7(11):. doi:
10.1172/jci.insight.157432. [PMID: 35472001] - Aditya Shah, John C O'Horo. In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
Annals of internal medicine.
2022 06; 175(6):JC64. doi:
10.7326/j22-0033. [PMID: 35667076] - Kathryn Biddle, Jonathan White, Nidhi Sofat. What is the full potential of baricitinib in treating patients with COVID-19?.
Expert review of clinical immunology.
2022 Jun; 18(6):545-549. doi:
10.1080/1744666x.2022.2072298. [PMID: 35486502] - Ross D Jansen-van Vuuren, Rahul Vohra. Synthesis of [2 H5 ]baricitinib via [2 H5 ]ethanesulfonyl chloride.
Journal of labelled compounds & radiopharmaceuticals.
2022 05; 65(6):156-161. doi:
10.1002/jlcr.3969. [PMID: 35277889] - M Waibel, H E Thomas, J M Wentworth, J J Couper, R J MacIsaac, F J Cameron, M So, B Krishnamurthy, M C Doyle, T W Kay. Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)-study protocol for a phase 2, randomized, placebo controlled trial.
Trials.
2022 May; 23(1):433. doi:
10.1186/s13063-022-06356-z. [PMID: 35606820] - Efstratios Gavriilidis, Christina Antoniadou, Akrivi Chrysanthopoulou, Maria Ntinopoulou, Andreas Smyrlis, Iliana Fotiadou, Nikoleta Zioga, Dionysios Kogias, Anastasia-Maria Natsi, Christos Pelekoudas, Evangelia Satiridou, Stefania-Aspasia Bakola, Charalampos Papagoras, Ioannis Mitroulis, Paschalis Peichamperis, Dimitrios Mikroulis, Vasileios Papadopoulos, Panagiotis Skendros, Konstantinos Ritis. Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure.
Clinical immunology (Orlando, Fla.).
2022 05; 238(?):109016. doi:
10.1016/j.clim.2022.109016. [PMID: 35447311] - Yuto Yasuda, Yutaka Hirayama, Kiyoshi Uemasu, Soichi Arasawa, Daisuke Iwashima, Ken-Ichi Takahashi. Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study.
Respiratory medicine and research.
2022 May; 81(?):100903. doi:
10.1016/j.resmer.2022.100903. [PMID: 35316675] - Takuya Tanimoto, Shinpei Tada, Suguru Fujita, Tetsu Hirakawa, Mirai Matsumura, Shoko Isoyama, Sayaka Ueno, Kosuke Hamai, Naoki Tsuji, Hideyasu Hirosawa, Tomohiro Taniguchi, Takeshi Okamoto, Takuji Omoto, Shinji Kusunoki, Hiroyuki Maeda, Nobuhisa Ishikawa. Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.
Respiratory investigation.
2022 May; 60(3):418-424. doi:
10.1016/j.resinv.2022.02.004. [PMID: 35307364] - Yuichi Kojima, Sho Nakakubo, Nozomu Takei, Keisuke Kamada, Yu Yamashita, Junichi Nakamura, Munehiro Matsumoto, Hiroshi Horii, Kazuki Sato, Hideki Shima, Masaru Suzuki, Satoshi Konno. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
Medicina (Kaunas, Lithuania).
2022 Apr; 58(4):. doi:
10.3390/medicina58040513. [PMID: 35454352] - Debasish Das, Prabuddha Mukhopadhyay, Debtanu Banerjee. Mortality comparision in patients receiving either Remdesivir or Remdesivir plus Baricitinib combination in case of moderate to severe COVID-19 Pneumonia: A retrospective study.
The Journal of the Association of Physicians of India.
2022 Apr; 70(4):11-12. doi:
NULL. [PMID: 35443520] - E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, Stephanie de Bono, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, José Francisco Kerr Saraiva, Sujatro Chakladar, Vincent C Marconi. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
The Lancet. Respiratory medicine.
2022 04; 10(4):327-336. doi:
10.1016/s2213-2600(22)00006-6. [PMID: 35123660] - Zhiwei Lin, Jianyi Niu, Yifan Xu, Lijie Qin, Jiabin Ding, Luqian Zhou. Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
Journal of medical virology.
2022 04; 94(4):1523-1534. doi:
10.1002/jmv.27482. [PMID: 34846766] - Mostafa Akbarzadeh-Khiavi, Mitra Torabi, Leila Rahbarnia, Azam Safary. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection.
Infection.
2022 Apr; 50(2):295-308. doi:
10.1007/s15010-021-01730-6. [PMID: 34902115] - Alexander Supady, Robert Zeiser. Baricitinib for patients with severe COVID-19-time to change the standard of care?.
The Lancet. Respiratory medicine.
2022 04; 10(4):314-315. doi:
10.1016/s2213-2600(22)00021-2. [PMID: 35123659] - Y Saishoji, Y Izumi, Y Otsuka, H Yura. COVID-19 with baricitinib-induced symptomatic creatinine kinase elevation.
QJM : monthly journal of the Association of Physicians.
2022 03; 115(3):155-156. doi:
10.1093/qjmed/hcac004. [PMID: 35026023] - Foad Rommasi, Mohammad Javad Nasiri, Mehdi Mirsaeidi. Immunomodulatory agents for COVID-19 treatment: possible mechanism of action and immunopathology features.
Molecular and cellular biochemistry.
2022 Mar; 477(3):711-726. doi:
10.1007/s11010-021-04325-9. [PMID: 35013850] - Rubén Iglesias Gómez, Raúl Méndez, Tomás Palanques-Pastor, Octavio Ballesta-López, Conxa Borrás Almenar, Juan Eduardo Megías Vericat, Eduardo López-Briz, Isabel Font-Noguera, Rosario Menéndez Villanueva, José Andrés Román Iborra, José Luis Poveda Andrés. Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients.
European journal of hospital pharmacy : science and practice.
2022 03; 29(e1):e41-e45. doi:
10.1136/ejhpharm-2021-002741. [PMID: 34321249] - José Rosas, Francisco Pasquau Liaño, Mónica Llombart Cantó, José María Carrasco Barea, Amparo Raga Beser, José Tomás Algado Rabasa, Francisco Martínez Adsuar, Brian Vila Auli, Isabel Fernández López, Ana María Garijo Sainz, Pere Esquerdo Ramis, Laura Ruiz Pérez, Mª Luisa Navarrete Rebollo, Raquel Hernández Lorido, Laura Gómez Escolar. Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study.
Reumatologia clinica.
2022 Mar; 18(3):150-156. doi:
10.1016/j.reumae.2020.10.006. [PMID: 35277213] - Amer Al-Musa, Brenna LaBere, Saddiq Habiballah, Alan A Nguyen, Janet Chou. Advances in clinical outcomes: What we have learned during the COVID-19 pandemic.
The Journal of allergy and clinical immunology.
2022 02; 149(2):569-578. doi:
10.1016/j.jaci.2021.12.775. [PMID: 34958811] - Diana Duong. COVID-19: severe resource crisis in hospitals.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
2022 01; 194(4):E131. doi:
10.1503/cmaj.1095984. [PMID: 35101875] - Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd-Rüdiger R Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John D Isaacs, Isabelle Koné-Paut, César Magro-Checa, Iain B McInnes, Pier Luigi Meroni, Luca Quartuccio, A V Ramanan, Manuel Ramos-Casals, Javier Rodríguez Carrio, Hendrik Schulze-Koops, Tanja A Stamm, Sander W Tas, Benjamin Terrier, Dennis G McGonagle, Xavier Mariette. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
Annals of the rheumatic diseases.
2022 01; 81(1):34-40. doi:
10.1136/annrheumdis-2021-221366. [PMID: 34620584] - Kari Kelton, Tim Klein, Dan Murphy, Mark Belger, Erik Hille, Patrick L McCollam, Theodore Spiro, Russel Burge. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
Advances in therapy.
2022 01; 39(1):562-582. doi:
10.1007/s12325-021-01982-6. [PMID: 34807369] - Antonio Vitiello, Francesco Ferrara. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Molecular biology reports.
2022 Jan; 49(1):827-831. doi:
10.1007/s11033-021-06888-8. [PMID: 34839450] - Antonio Vitiello, Francesco Ferrara. Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection.
Naunyn-Schmiedeberg's archives of pharmacology.
2022 01; 395(1):99-104. doi:
10.1007/s00210-021-02169-0. [PMID: 34669002] - Frank L van de Veerdonk, Evangelos Giamarellos-Bourboulis, Peter Pickkers, Lennie Derde, Helen Leavis, Reinout van Crevel, Job J Engel, W Joost Wiersinga, Alexander P J Vlaar, Manu Shankar-Hari, Tom van der Poll, Marc Bonten, Derek C Angus, Jos W M van der Meer, Mihai G Netea. A guide to immunotherapy for COVID-19.
Nature medicine.
2022 01; 28(1):39-50. doi:
10.1038/s41591-021-01643-9. [PMID: 35064248] - Alexandre Naime Barbosa, Antonio Silvinato, Hélio Bacha, Idevaldo Floriano, Suzana Tanni, Wanderley Bernardo. Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.
Revista da Associacao Medica Brasileira (1992).
2022 01; 68(1):3-8. doi:
10.1590/1806-9282.2022d681. [PMID: 35239928] - Md Khalid Anwer, Essam A Ali, Muzaffar Iqbal, Mohammed Muqtader Ahmed, Mohammed F Aldawsari, Ahmed Al Saqr, Mohd Nazam Ansari, M Ali Aboudzadeh. Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability.
Molecules (Basel, Switzerland).
2021 Dec; 27(1):. doi:
10.3390/molecules27010168. [PMID: 35011397] - Jia Li, Yuetian Yu, Jingjing Xie, Yan Jiang, Liangjing Lu. Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib.
Rheumatology (Oxford, England).
2021 12; 61(1):e6-e7. doi:
10.1093/rheumatology/keab658. [PMID: 34424311] - Boghuma K Titanji, Monica M Farley, Raymond F Schinazi, Vincent C Marconi. Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 12; 73(11):e3980-e3981. doi:
10.1093/cid/ciaa1210. [PMID: 32797226] - Sarah C J Jorgensen, Lisa Burry, Christopher L Y Tse, Linda D Dresser. Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 12; 73(11):e3978-e3979. doi:
10.1093/cid/ciaa1208. [PMID: 32797237] - Christopher Cerda-Contreras, Laura Nuzzolo-Shihadeh, Adrián Camacho-Ortiz, Eduardo Perez-Alba. Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 12; 73(11):e3977-e3978. doi:
10.1093/cid/ciaa1209. [PMID: 32797239] - Tom Le Voyer, Cyril Gitiaux, François-Jérôme Authier, Christine Bodemer, Isabelle Melki, Pierre Quartier, Florence Aeschlimann, Arnaud Isapof, Jean Philippe Herbeuval, Vincent Bondet, Jean-Luc Charuel, Marie-Louise Frémond, Darragh Duffy, Mathieu P Rodero, Brigitte Bader-Meunier. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Rheumatology (Oxford, England).
2021 12; 60(12):5801-5808. doi:
10.1093/rheumatology/keab116. [PMID: 33576769] - Vincent C Marconi, Athimalaipet V Ramanan, Stephanie de Bono, Cynthia E Kartman, Venkatesh Krishnan, Ran Liao, Maria Lucia B Piruzeli, Jason D Goldman, Jorge Alatorre-Alexander, Rita de Cassia Pellegrini, Vicente Estrada, Mousumi Som, Anabela Cardoso, Sujatro Chakladar, Brenda Crowe, Paulo Reis, Xin Zhang, David H Adams, E Wesley Ely. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
The Lancet. Respiratory medicine.
2021 12; 9(12):1407-1418. doi:
10.1016/s2213-2600(21)00331-3. [PMID: 34480861] - Andre C Kalil, Justin Stebbing. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.
The Lancet. Respiratory medicine.
2021 12; 9(12):1349-1351. doi:
10.1016/s2213-2600(21)00358-1. [PMID: 34480862] - Boris Hügle, Manuela Krumrey-Langkammerer, Johannes-Peter Haas. Infection with SARS-CoV-2 causes flares in patients with juvenile idiopathic arthritis in remission or inactive disease on medication.
Pediatric rheumatology online journal.
2021 Nov; 19(1):163. doi:
10.1186/s12969-021-00653-8. [PMID: 34844609] - Daniel Hornuss, Roland Giesen, Paul Biever, Winfried V Kern. [Clinical benefit of Tocilizumab and other immunomodulating agents for treatment of COVID-19].
Deutsche medizinische Wochenschrift (1946).
2021 Nov; 146(23):1538-1542. doi:
10.1055/a-1643-4209. [PMID: 34826840] - Takehiro Izumo, Naoyuki Kuse, Nobuyasu Awano, Mari Tone, Keita Sakamoto, Kohei Takada, Yutaka Muto, Kazushi Fujimoto, Ayae Saiki, Yu Ito, Haruko Matsumoto, Minoru Inomata. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19.
Respiratory investigation.
2021 Nov; 59(6):799-803. doi:
10.1016/j.resinv.2021.07.004. [PMID: 34413006] - Robert Ohsfeldt, Kari Kelton, Tim Klein, Mark Belger, Patrick L Mc Collam, Theodore Spiro, Russel Burge, Neera Ahuja. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
Clinical therapeutics.
2021 11; 43(11):1877-1893.e4. doi:
10.1016/j.clinthera.2021.09.016. [PMID: 34732289] - Sujoy Khan. Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?.
Rheumatology (Oxford, England).
2021 10; 60(10):e371. doi:
10.1093/rheumatology/keab386. [PMID: 33895812] - Pedro Abizanda, Juan María Calbo Mayo, Marta Mas Romero, Elisa Belén Cortés Zamora, María Teresa Tabernero Sahuquillo, Luis Romero Rizos, Pedro Manuel Sánchez-Jurado, Ginés Sánchez-Nievas, Carlos Campayo Escolano, Alba Ochoa Serrano, Victoria Sánchez-Flor Alfaro, Rita López Bru, Cristina Gómez Ballesteros, David Caldevilla Bernardo, Francisco Javier Callejas González, Fernando Andrés-Pretel, Volker Martin Lauschke, Justin Stebbing. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia.
Journal of the American Geriatrics Society.
2021 10; 69(10):2752-2758. doi:
10.1111/jgs.17357. [PMID: 34235720] - Ching-Yi Chen, Wang-Chun Chen, Chi-Kuei Hsu, Chien-Ming Chao, Chih-Cheng Lai. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
International immunopharmacology.
2021 Oct; 99(?):108027. doi:
10.1016/j.intimp.2021.108027. [PMID: 34343937] - Eduardo Pérez-Alba, Laura Nuzzolo-Shihadeh, Gloria Mayela Aguirre-García, Jaime Espinosa-Mora, Juan Diego Lecona-Garcia, Romulo Omar Flores-Pérez, Marisela Mendoza-Garza, Adrián Camacho-Ortiz. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
2021 Oct; 54(5):787-793. doi:
10.1016/j.jmii.2021.05.009. [PMID: 34294593] - Sara Assadiasl, Yousef Fatahi, Banafsheh Mosharmovahed, Bahareh Mohebbi, Mohammad Hossein Nicknam. Baricitinib: From Rheumatoid Arthritis to COVID-19.
Journal of clinical pharmacology.
2021 10; 61(10):1274-1285. doi:
10.1002/jcph.1874. [PMID: 33870531] - Qinglin Cheng, Junfang Chen, Qingjun Jia, Zijian Fang, Gang Zhao. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials.
Aging.
2021 09; 13(18):21866-21902. doi:
10.18632/aging.203522. [PMID: 34531332] - Marina Chan, Siddharth Vijay, John McNevin, M Juliana McElrath, Eric C Holland, Taranjit S Gujral. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release.
Molecular systems biology.
2021 09; 17(9):e10426. doi:
10.15252/msb.202110426. [PMID: 34486798] - Hao-Yu Wu, Chien-Ting Pan, Chiao-Feng Cheng, Chi-Ying Lin, Sheng-Nan Chang, Yi-Chung Chen, Chih-Yuan Wang, Yen-Fu Chen, Chung-Yu Chen, Matthew Huei-Ming Ma, Juey-Jen Hwang. Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.
Journal of the Formosan Medical Association = Taiwan yi zhi.
2021 Sep; 120(9):1777-1781. doi:
10.1016/j.jfma.2021.03.014. [PMID: 33838985] - Chong-Xiang Chen, Jiao-Jiao Wang, Huan Li, Le-Tao Yuan, Robert Peter Gale, Yang Liang. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
Leukemia.
2021 09; 35(9):2616-2620. doi:
10.1038/s41375-021-01266-6. [PMID: 33990684] - Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, Grigory Rodoman, Arkady Vertkin, Alena Zagrebneva, Justin Stebbing. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Annals of the rheumatic diseases.
2021 09; 80(9):1245-1246. doi:
10.1136/annrheumdis-2021-220049. [PMID: 34099486] - Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Annals of the rheumatic diseases.
2021 07; 80(7):865-875. doi:
10.1136/annrheumdis-2020-219012. [PMID: 33741556] - Giacomo Maria Guidelli, Ombretta Viapiana, Nicoletta Luciano, Maria De Santis, Nicola Boffini, Luca Quartuccio, Domenico Birra, Edoardo Conticini, Maria Sole Chimenti, Chiara Bazzani, Eleonora Bruschi, Marta Riva, Lorenzo Maria Canziani, Gerolamo Bianchi, Maria Rosa Pozzi, Massimiliano Limonta, Roberto Gorla, Roberto Perricone, Bruno Frediani, Paolo Moscato, Salvatore De Vita, Lorenzo Dagna, Maurizio Rossini, Carlo Selmi. Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
Clinical and experimental rheumatology.
2021 Jul; 39(4):868-873. doi:
NULL. [PMID: 33338001] - Dirk M Elston. This Month in JAAD: July 2021.
Journal of the American Academy of Dermatology.
2021 07; 85(1):33. doi:
10.1016/j.jaad.2021.04.039. [PMID: 33975759] - Cláudia Monfroni Rocha, Alessandro Menna Alves, Beatriz Fabris Bettanin, Fernanda Majolo, Matthias Gehringer, Stefan Laufer, Márcia Inês Goettert. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Inflammopharmacology.
2021 Jun; 29(3):595-615. doi:
10.1007/s10787-021-00822-x. [PMID: 34046798] - Md Jahidul Hasan, Raihan Rabbani, Ahmad Mursel Anam, Shihan Mahmud Redwanul Huq, Mohammad Mufizul Islam Polash, Shahzadi Sayeeda Tun Nessa, Sitesh C Bachar. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
BMC infectious diseases.
2021 May; 21(1):427. doi:
10.1186/s12879-021-06119-2. [PMID: 33962573] - Farzan Solimani, Katharina Meier, Kamran Ghoreschi. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
European journal of immunology.
2021 05; 51(5):1071-1075. doi:
10.1002/eji.202149173. [PMID: 33675065] - William H Frishman. The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 5.
Cardiology in review.
2021 May; 29(3):109. doi:
10.1097/crd.0000000000000386. [PMID: 33758124] - Boghuma K Titanji, Monica M Farley, Ashish Mehta, Randi Connor-Schuler, Abeer Moanna, Sushma K Cribbs, Jesse O'Shea, Kathryn DeSilva, Bonnie Chan, Alex Edwards, Christina Gavegnano, Raymond F Schinazi, Vincent C Marconi. Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 04; 72(7):1247-1250. doi:
10.1093/cid/ciaa879. [PMID: 32597466] - Tania Gudu, Carmel Stober, Andrew P Cope, Joseph Cheriyan, James Galloway, Ian B Wilkinson, Michalis Kostapanos, David Jayne, Frances Hall. Baricitinib set to join the Covid-19 therapeutic arsenal?.
Rheumatology (Oxford, England).
2021 04; 60(4):1585-1587. doi:
10.1093/rheumatology/keab061. [PMID: 33502499] - Juan Li, Hong-Hui Liu, Xiao-Dong Yin, Cheng-Cheng Li, Jing Wang. COVID-19 illness and autoimmune diseases: recent insights.
Inflammation research : official journal of the European Histamine Research Society ... [et al.].
2021 Apr; 70(4):407-428. doi:
10.1007/s00011-021-01446-1. [PMID: 33640999] - Linda Petrone, Elisa Petruccioli, Tonino Alonzi, Valentina Vanini, Gilda Cuzzi, Saeid Najafi Fard, Concetta Castilletti, Fabrizio Palmieri, Gina Gualano, Pietro Vittozzi, Emanuele Nicastri, Luciana Lepore, Alba Grifoni, Andrea Antinori, Alessandra Vergori, Giuseppe Ippolito, Fabrizio Cantini, Delia Goletti. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
The Journal of infection.
2021 04; 82(4):58-66. doi:
10.1016/j.jinf.2021.02.023. [PMID: 33639176] - Andre C Kalil, Thomas F Patterson, Aneesh K Mehta, Kay M Tomashek, Cameron R Wolfe, Varduhi Ghazaryan, Vincent C Marconi, Guillermo M Ruiz-Palacios, Lanny Hsieh, Susan Kline, Victor Tapson, Nicole M Iovine, Mamta K Jain, Daniel A Sweeney, Hana M El Sahly, Angela R Branche, Justino Regalado Pineda, David C Lye, Uriel Sandkovsky, Anne F Luetkemeyer, Stuart H Cohen, Robert W Finberg, Patrick E H Jackson, Babafemi Taiwo, Catharine I Paules, Henry Arguinchona, Nathaniel Erdmann, Neera Ahuja, Maria Frank, Myoung-Don Oh, Eu-Suk Kim, Seow Y Tan, Richard A Mularski, Henrik Nielsen, Philip O Ponce, Barbara S Taylor, LuAnn Larson, Nadine G Rouphael, Youssef Saklawi, Valeria D Cantos, Emily R Ko, John J Engemann, Alpesh N Amin, Miki Watanabe, Joanne Billings, Marie-Carmelle Elie, Richard T Davey, Timothy H Burgess, Jennifer Ferreira, Michelle Green, Mat Makowski, Anabela Cardoso, Stephanie de Bono, Tyler Bonnett, Michael Proschan, Gregory A Deye, Walla Dempsey, Seema U Nayak, Lori E Dodd, John H Beigel. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
The New England journal of medicine.
2021 03; 384(9):795-807. doi:
10.1056/nejmoa2031994. [PMID: 33306283] - Delia Goletti, Fabrizio Cantini. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
The New England journal of medicine.
2021 03; 384(9):867-869. doi:
10.1056/nejme2034982. [PMID: 33657299] - Eleanor Quek, Hasan Tahir, Poornima Kumar, Robert Hastings, Rajeev Jha. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
British journal of hospital medicine (London, England : 2005).
2021 Mar; 82(3):1-9. doi:
10.12968/hmed.2021.0112. [PMID: 33792391] - Xuan-Qi Zheng, Jin-Feng Huang, Jia-Liang Lin, Ya-Xin Zhu, Min-Qi Wang, Mei-Liang Guo, Xing-Jie Zan, Ai-Min Wu. Controlled release of baricitinib from a thermos-responsive hydrogel system inhibits inflammation by suppressing JAK2/STAT3 pathway in acute spinal cord injury.
Colloids and surfaces. B, Biointerfaces.
2021 Mar; 199(?):111532. doi:
10.1016/j.colsurfb.2020.111532. [PMID: 33385822] - G Moreno-González, A Mussetti, A Albasanz-Puig, I Salvador, A Sureda, C Gudiol, R Salazar, M Marin, M Garcia, V Navarro, I de la Haba Vaca, E Coma, G Sanz-Linares, X Dura, S Fontanals, G Serrano, C Cruz, R Mañez. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Trials.
2021 Feb; 22(1):116. doi:
10.1186/s13063-021-05072-4. [PMID: 33546739] - Fabiola Atzeni, Elisabetta Gerratana, Manuela Giallanza, Laura La Corte, Valeria Nucera, Gianfranco Miceli, Donatella Sangari, Ignazio Francesco Masala. The effect of drugs used in rheumatology for treating SARS-CoV2 infection.
Expert opinion on biological therapy.
2021 02; 21(2):219-228. doi:
10.1080/14712598.2020.1817372. [PMID: 32866053] - Shintaro Akiyama, Akihiro Yamada, Atsushi Sakuraba. Safety of nontumor necrosis factor-targeted biologics in the COVID-19 pandemic.
Journal of medical virology.
2021 02; 93(2):714-716. doi:
10.1002/jmv.26528. [PMID: 32949157] - Arindam Banerjee, Rudra Prosad Goswami, Moumita Chatterjee. Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19.
Scientific reports.
2021 01; 11(1):2512. doi:
10.1038/s41598-021-82139-x. [PMID: 33510353] - Timothy N Hoang, Maria Pino, Arun K Boddapati, Elise G Viox, Carly E Starke, Amit A Upadhyay, Sanjeev Gumber, Michael Nekorchuk, Kathleen Busman-Sahay, Zachary Strongin, Justin L Harper, Gregory K Tharp, Kathryn L Pellegrini, Shannon Kirejczyk, Keivan Zandi, Sijia Tao, Tristan R Horton, Elizabeth N Beagle, Ernestine A Mahar, Michelle Y H Lee, Joyce Cohen, Sherrie M Jean, Jennifer S Wood, Fawn Connor-Stroud, Rachelle L Stammen, Olivia M Delmas, Shelly Wang, Kimberly A Cooney, Michael N Sayegh, Lanfang Wang, Peter D Filev, Daniela Weiskopf, Guido Silvestri, Jesse Waggoner, Anne Piantadosi, Sudhir P Kasturi, Hilmi Al-Shakhshir, Susan P Ribeiro, Rafick P Sekaly, Rebecca D Levit, Jacob D Estes, Thomas H Vanderford, Raymond F Schinazi, Steven E Bosinger, Mirko Paiardini. Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.
Cell.
2021 01; 184(2):460-475.e21. doi:
10.1016/j.cell.2020.11.007. [PMID: 33278358] - Jose Luis Rodriguez-Garcia, Gines Sanchez-Nievas, Juan Arevalo-Serrano, Cristina Garcia-Gomez, Jose Maria Jimenez-Vizuete, Elisa Martinez-Alfaro. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
Rheumatology (Oxford, England).
2021 01; 60(1):399-407. doi:
10.1093/rheumatology/keaa587. [PMID: 33020836] - Chun Dang, Yaoheng Lu, Xingyu Chen, Qian Li. Baricitinib Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating the Janus Kinase/Signal Transducer and Activator of Transcription Signaling Pathway.
Frontiers in immunology.
2021; 12(?):650708. doi:
10.3389/fimmu.2021.650708. [PMID: 33927721] - Jae Seok Kim, Jun Young Lee, Jae Won Yang, Keum Hwa Lee, Maria Effenberger, Wladimir Szpirt, Andreas Kronbichler, Jae Il Shin. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Theranostics.
2021; 11(1):316-329. doi:
10.7150/thno.49713. [PMID: 33391477] - Michael Putman, Yu Pei Eugenia Chock, Herman Tam, Alfred H J Kim, Sebastian E Sattui, Francis Berenbaum, Maria I Danila, Peter Korsten, Catalina Sanchez-Alvarez, Jeffrey A Sparks, Laura C Coates, Candace Palmerlee, Andrea Peirce, Arundathi Jayatilleke, Sindhu R Johnson, Adam Kilian, Jean Liew, Larry J Prokop, M Hassan Murad, Rebecca Grainger, Zachary S Wallace, Alí Duarte-García. Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Arthritis & rheumatology (Hoboken, N.J.).
2021 01; 73(1):36-47. doi:
10.1002/art.41469. [PMID: 32741139] - Ambedkar Kumar Yadav, Siwan Wen, Xianghuai Xu, Li Yu. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
Annals of palliative medicine.
2021 Jan; 10(1):707-720. doi:
10.21037/apm-20-1755. [PMID: 33440983] - Eeda Koti Reddy, Srisravanthi Battula, Shaik Anwar, Ayyiliath M Sajith. Drug Re-purposing Approach and Potential Therapeutic Strategies to Treat COVID-19.
Mini reviews in medicinal chemistry.
2021; 21(6):704-723. doi:
10.2174/1389557520666201113105940. [PMID: 33185159] - Justin Stebbing, Ginés Sánchez Nievas, Marco Falcone, Sonia Youhanna, Peter Richardson, Silvia Ottaviani, Joanne X Shen, Christian Sommerauer, Giusy Tiseo, Lorenzo Ghiadoni, Agostino Virdis, Fabio Monzani, Luis Romero Rizos, Francesco Forfori, Almudena Avendaño Céspedes, Salvatore De Marco, Laura Carrozzi, Fabio Lena, Pedro Manuel Sánchez-Jurado, Leonardo Gianluca Lacerenza, Nencioni Cesira, David Caldevilla Bernardo, Antonio Perrella, Laura Niccoli, Lourdes Sáez Méndez, Daniela Matarrese, Delia Goletti, Yee-Joo Tan, Vanessa Monteil, George Dranitsaris, Fabrizio Cantini, Alessio Farcomeni, Shuchismita Dutta, Stephen K Burley, Haibo Zhang, Mauro Pistello, William Li, Marta Mas Romero, Fernando Andrés Pretel, Rafaela Sánchez Simón-Talero, Rafael García-Molina, Claudia Kutter, James H Felce, Zehra F Nizami, Andras G Miklosi, Josef M Penninger, Francesco Menichetti, Ali Mirazimi, Pedro Abizanda, Volker M Lauschke. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality.
Science advances.
2021 01; 7(1):. doi:
10.1126/sciadv.abe4724. [PMID: 33187978] - NULL. An EUA for baricitinib (Olumiant) for COVID-19.
The Medical letter on drugs and therapeutics.
2020 12; 62(1614):202-203. doi:
NULL. [PMID: 33451175] - Eric J Rubin, Lindsey R Baden, Stephen Morrissey. Audio Interview: Covid-19 Vaccine Fundamentals.
The New England journal of medicine.
2020 12; 383(25):e146. doi:
10.1056/nejme2035370. [PMID: 33326722] - Vincenzo Bronte, Stefano Ugel, Elisa Tinazzi, Antonio Vella, Francesco De Sanctis, Stefania Canè, Veronica Batani, Rosalinda Trovato, Alessandra Fiore, Varvara Petrova, Francesca Hofer, Roza Maria Barouni, Chiara Musiu, Simone Caligola, Laura Pinton, Lorena Torroni, Enrico Polati, Katia Donadello, Simonetta Friso, Francesca Pizzolo, Manuela Iezzi, Federica Facciotti, Pier Giuseppe Pelicci, Daniela Righetti, Paolo Bazzoni, Mariaelisa Rampudda, Andrea Comel, Walter Mosaner, Claudio Lunardi, Oliviero Olivieri. Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
The Journal of clinical investigation.
2020 12; 130(12):6409-6416. doi:
10.1172/jci141772. [PMID: 32809969] - Xia Zhao, Xiao Yan Sheng, Christopher D Payne, Xin Zhang, Feng Wang, Yi Min Cui. Pharmacokinetics, Safety, and Tolerability of Single- and Multiple-Dose Once-Daily Baricitinib in Healthy Chinese Subjects: A Randomized Placebo-Controlled Study.
Clinical pharmacology in drug development.
2020 11; 9(8):952-960. doi:
10.1002/cpdd.868. [PMID: 32945153] - Sergio Lo Caputo, Gaetano Corso, Mario Clerici, Teresa Antonia Santantonio. Baricitinib: A chance to treat COVID-19?.
Journal of medical virology.
2020 11; 92(11):2343-2344. doi:
10.1002/jmv.26033. [PMID: 32437019] - Ling Peng, Kui Xiao, Silvia Ottaviani, Justin Stebbing, Ying-Jie Wang. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Expert opinion on drug safety.
2020 Nov; 19(11):1505-1511. doi:
10.1080/14740338.2020.1799975. [PMID: 32693646] - Thomas Dörner, Yoshiya Tanaka, Michelle A Petri, Josef S Smolen, Daniel J Wallace, Ernst R Dow, Richard E Higgs, Guilherme Rocha, Brenda Crowe, Robert J Benschop, Nicole L Byers, Maria E Silk, Stephanie de Bono, Damiano Fantini, Robert W Hoffman. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Lupus science & medicine.
2020 10; 7(1):. doi:
10.1136/lupus-2020-000424. [PMID: 33037080] - A Cingolani, A M Tummolo, G Montemurro, E Gremese, L Larosa, M C Cipriani, G Pasciuto, R Liperoti, R Murri, T Pirronti, R Cauda, M Fantoni. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Infection.
2020 Oct; 48(5):767-771. doi:
10.1007/s15010-020-01476-7. [PMID: 32642806] - Jeong Seok Lee, Eui-Cheol Shin. The type I interferon response in COVID-19: implications for treatment.
Nature reviews. Immunology.
2020 10; 20(10):585-586. doi:
10.1038/s41577-020-00429-3. [PMID: 32788708] - Emanuel Raschi, Paolo Caraceni, Elisabetta Poluzzi, Fabrizio De Ponti. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?.
Expert opinion on drug safety.
2020 10; 19(10):1367-1369. doi:
10.1080/14740338.2020.1812191. [PMID: 32840116] - Xian Chen, Yuheng Shan, Yingyu Wen, Jia Sun, Haike Du. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects.
The Journal of infection.
2020 10; 81(4):647-679. doi:
10.1016/j.jinf.2020.05.020. [PMID: 32422152] - Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Daniela Matarrese, Massimo Edoardo Di Natale, Pamela Lotti, Donatella Aquilini, Giancarlo Landini, Barbara Cimolato, Massimo Antonio Di Pietro, Michele Trezzi, Paolo Stobbione, Gabriele Frausini, Assunta Navarra, Emanuele Nicastri, Giovanni Sotgiu, Delia Goletti. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
The Journal of infection.
2020 10; 81(4):647-679. doi:
10.1016/j.jinf.2020.06.052. [PMID: 32592703]